Clinical trials
Cancer clinical trials
Below are recruiting cancer clinical trials, each written for real people, not researchers. We’re tracking 13,144 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06944262Recruiting
Cancer-related stress study for patients and caregivers
This study looks at stress after a cancer diagnosis and asks patients and caregivers what kind of support they want. It may help improve care for people coping with cancer.
Lille, NordAges 18 years+ - NCT06944457RecruitingPhase 1
Safety Study of MPD-1 for Advanced Solid Tumors
This trial tests a new drug called MPD-1 for people with advanced solid tumors that have not responded to standard treatments. It focuses on patients with specific genetic changes (KRAS mutation or PTEN loss) to see if the drug is safe and how the body processes it.
SeoulAges 19–75 - NCT06945484Recruiting
Exercise program for lung cancer before surgery
This trial tests whether a personalized exercise plan can help people with lung cancer who are getting chemotherapy or immunotherapy before surgery. You’ll be asked to follow an exercise routine during your treatment.
Galveston, TexasAges 18 years+ - NCT06945757Recruiting
Physical activity rehab program for adult cancer patients
This program tests a rehabilitation plan that includes physical activity for people with cancer. It is designed to help you stay active during or after treatment.
Lucerne, Canton of LucerneAges 18–80 - NCT06945718Recruiting
Green dye test for gastric cancer surgery
This trial tests whether a green dye called indocyanine green can help surgeons find and remove more lymph nodes during laparoscopic surgery for advanced stomach cancer. It may improve the chances of removing all cancer.
Fuzhou, FujianAges 18–75 - NCT06945978Recruiting
Testing a blood test to predict treatment response in advanced pancreatic cancer
This study looks at a special blood test (miRNA panel) to see if it can help predict how well treatment works for people with advanced pancreatic cancer. If you are starting FOLFIRINOX for the first time, you may be able to join.
São Paulo, São PauloAges 18 years+ - NCT06946238Recruiting
Single-dose radiation after surgery for low-risk breast cancer
This trial tests giving a single, very targeted dose of radiation right after surgery for early-stage breast cancer. It is for women age 40+ with small, low-risk tumors (Luminal A or B) that have been fully removed and have not spread to lymph nodes.
MilanAges 40 years+ - NCT06949098RecruitingPhase 2
Local tumor removal plus chemo-radiation for early low rectal cancer
This trial tests whether removing just the tumor locally, followed by chemotherapy and radiation, is effective for early-stage (T1-2 N0) rectal cancers located low or very low in the rectum. It may help you keep your anal opening and avoid major surgery that requires a permanent colostomy bag.
Shijiazhuang, HebeiAges 18–75 - NCT06949982RecruitingPhase 2
Comparing two treatments for advanced colorectal cancer with RAS mutations
This trial tests if a combination of hydroxychloroquine, methotrexate, capecitabine, and bevacizumab works better than regorafenib for people with metastatic colorectal cancer that has a RAS gene mutation and has stopped responding to at least two prior treatments.
Saint Petersburg, Sankt-PeterburgAges 18 years+ - NCT06950073Recruiting
Second radiation treatment for lung cancer in the chest
This study tests whether giving a second course of radiation to the chest (called retreatment) can control lung cancer that has come back or a new cancer that started there. People who have already had radiation to their chest and are healthy enough for more may be eligible.
Aarhus, JutlandAges Any age - NCT06950697Recruiting
Blood clot risk prediction for lung cancer patients on immunotherapy
This study builds a tool to predict blood clot risk in lung cancer patients receiving immune checkpoint inhibitors. Researchers will use your data to develop a more personalized risk assessment, which may help prevent dangerous clots during treatment.
Zhengzhou, HenanAges 18 years+ - NCT06953999RecruitingPhase 3
Testing immunotherapy plus chemo for metastatic pancreatic cancer
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
Harbin, HeilongjiangAges 18–75 - NCT06954233Recruiting
Urination and erections after lymph node surgery for testicular cancer
This study looks at how removing lymph nodes in the back of the belly for testicular cancer affects urination and erectile function. It may help patients understand what to expect after this surgery.
Krakow, MalopolskaAges 18 years+ - NCT06954246RecruitingPhase 3
New drug vs. doctor’s choice for relapsed small cell lung cancer
This trial tests a new drug called MHB088C for people with small cell lung cancer that has come back or gotten worse after standard treatments. It compares this drug to other options your doctor might choose. The goal is to see if MHB088C works better.
ShanghaiAges 18 years+ - NCT06954480RecruitingPhase 2
Two drugs vs one for PDL1-negative breast cancer
This trial tests a new combination of two drugs (datopotamab deruxtecan plus durvalumab) against one drug alone (datopotamab deruxtecan) for people with PDL1-negative, triple-negative breast cancer that has spread. The goal is to see if the combination works better.
LondonAges 18 years+ - NCT06954584RecruitingPhase 3
Fluzoparib with or without bevacizumab or diet for advanced ovarian cancer
This trial tests if adding bevacizumab (a drug that blocks blood vessel growth) or a special diet to fluzoparib (a PARP inhibitor) works better than fluzoparib alone for women with advanced ovarian cancer whose tumors have specific genetic features (HRD-positive or HRD-negative). It is for patients who have already responded well to initial chemotherapy.
Wuhan, HubeiAges 18 years+ - NCT06954623Recruiting
Partial breast re-irradiation for breast cancer recurrence
This trial tests a second round of radiation to just part of the breast for women who had a previous lumpectomy and radiation, and now have a small, early-stage cancer or DCIS in the same breast. The goal is to see if a focused re-treatment is safe and effective.
HeidelbergAges 18 years+ - NCT06954961RecruitingPhase 3
Study of D-0502 for ER+ HER2- advanced breast cancer
This trial tests an oral drug called D-0502 for people with a specific type of advanced breast cancer (ER-positive, HER2-negative). It is for those whose cancer has returned or worsened after hormone therapy, and it may be an option before trying more chemotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT06955988RecruitingPhase 1
Safety and early results of AST2303 for advanced lung cancer
This trial tests a new oral drug, AST2303 (ABK3376), in people with advanced non-small cell lung cancer that has not responded to other treatments. It aims to see if the drug is safe and whether it can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06956040Recruiting
Family doctor involvement in lung cancer screening
This study tests whether having your family doctor offer you a lung cancer screening scan (low-dose CT) can help find cancer early. You may qualify if you are a current or former heavy smoker and can travel to a Paris hospital for the scan.
ParisAges 50–74 - NCT06956690RecruitingPhase 1/Phase 2
Testing HMBD-501 for HER3-positive advanced solid tumors
This trial tests a new drug, HMBD-501, for people with advanced solid tumors that have a specific protein called HER3. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06957314Recruiting
Hospital-at-home for people receiving Tarlatamab
This study tests giving hospital-type care at home for people with extensive-stage small cell lung cancer who are receiving the drug Tarlatamab. It aims to see if patients can safely receive their treatment at home instead of in the hospital.
Basking Ridge, New JerseyAges 18 years+ - NCT06958419RecruitingPhase 2/Phase 3
Short radiation plus targeted drugs for advanced colon cancer
This trial tests a combination of short-course radiation, chemotherapy, targeted therapy (bevacizumab), and an immunotherapy drug (PD-1 inhibitor) for people with advanced colorectal cancer that has spread and is not curable with surgery. It aims to see if this approach can help shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06958432RecruitingPhase 2/Phase 3
Short-course radiation plus chemo and immunotherapy for rectal cancer
This trial tests a treatment plan that uses a short course of radiation to the lymph nodes-sparing area, followed by chemotherapy and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of mid or low rectal cancer (pMMR/MSS). The goal is to see if this approach can shrink the tumor and improve outcomes without needing extensive surgery.
Guangzhou, GuangdongAges 18–75
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cancer?
- Yes. Clin2 currently lists 13,144 recruiting cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.